Hypertension worldwide
estimation and risk

5537ae1efdb0e2d6015c521d_1-completa.png
~30%
5537b2f05f1065d401ce0018_1-icon-A.png
of the population are HYPERTENSIVE (HTN)¹

Hypertension is a major risk factor for cardiovascular disease morbidity and mortality including myocardial infarction, congestive heart failure, stroke, renal disease and dementia.

5537b4fa76ee39080f7f177c_arrow-down.png
Even in individuals presumed stable, LESS THAN 1/3 are protected from subsequent strokes and hearth attacks²
5537b76a76ee39080f7f17da_1b-icon-1.png5537b79676ee39080f7f17df_1b-icon-2.png5537b7a376ee39080f7f17e0_1b-icon-3.png5537b7b0fdb0e2d6015c53d9_1b-icon-4.png
5537ba1b5f1065d401ce018c_2-completa.png
~20%
5537bb350219280a0ff0b3f5_2-icon-A.png
of hypertensive patients are RESISTANT HYPERTENSIVE (res-HTN)³

Their blood pressure usually remains above 140/90 mmHg despite the appropriate lifestyle measures and the provision of at least 3 anti-Hypertensive drugs.

Res-HTN has been associated with a 1.1-3 fold increase in the risk of cardiovascular events.

5537b4fa76ee39080f7f177c_arrow-down.png
5537bcd70219280a0ff0b490_3-completa.png
>23%
5537bd8a5f1065d401ce024d_3-icon-A.png
of Resistant HTN patients have
PRIMARY ALDOSTERONISM ³ ⁴

Primary aldosteronism (PA) is a type of hormonal disorder that leads to high blood pressure. Currently, PA is detected late (8-12 years after onset of hypertension).

Diagnosis and treatment of hypertension

TODAY
<4%
res-HTN patients tested

Too few Direct Renin/PRA and Aldosterone tests are prescribed by Specialists to exclude PA, leaving Renovascular Hypertension undiagnosed and untreated.

5537c41d5f1065d401ce040d_icon-omino-blu.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c49476ee39080f7f1b12_icon-omino-giallo.png
5537c5940219280a0ff0b5dc_icon-attention.png
Patients stay in limbo with increasing health risks
What we can do
100%
res-HTN patients tested

Test all res-HTN patients with Aldosterone and Direct Renin Assays for a rapid Primary Aldosteronism (PA) diagnosis. ¹ ⁵

5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png5537c41d5f1065d401ce040d_icon-omino-blu.png
A key to success in reducing mortality

Early diagnosis of PA leads to the administration of effective treatments, which can reduce the impact and improve prognosis.

The DiaSorin Solution: a simple test for PA diagnosis

LIAISON® Direct Renin and Aldosterone test for PA’s early diagnosis

The new combination of LIAISON® Direct Renin and Aldosterone automated assays allows meaningful PA diagnosis with a comparable specificity and sensitivity to existing methods